Medicaid obesity coverage count stands at 12 states and is set to fall again on October 1

The number of state Medicaid fee-for-service programs paying for GLP-1 drugs like Wegovy and Zepbound when they are prescribed for obesity alone stands at roughly 12 as of early September 2026. That is one fewer than KFF's January 2026 count of 13, after MassHealth stopped covering weight-loss-only prescriptions on July 1, 2026 ^[1]. A Rhode Island elimination of weight-management coverage is scheduled to take effect October 1, which would bring the count to 11; the state's own notice is not among the documents reviewed here, so details such as how many members are affected are not yet known.

The trend has been steadily downward. KFF counted 16 programs covering GLP-1s for obesity in October 2025 and 13 in January 2026, after California, New Hampshire, Pennsylvania and South Carolina dropped the benefit ^[1]. Medi-Cal Rx stopped covering Saxenda, Wegovy and Zepbound for weight loss on January 1, 2026, while keeping them with prior authorization for FDA-approved uses such as type 2 diabetes, cardiovascular disease and kidney disease, plus an EPSDT exception for children ^[1]. Pennsylvania ended weight-loss coverage for adults 21 and older on the same date, keeping under-21 coverage and other FDA indications ^[1]. Michigan did not drop coverage but narrowed it on January 1, 2026 to criteria including morbid obesity and documented failure of alternatives, honoring existing approvals for their six-month term ^[1].

Massachusetts was the biggest single change this summer. MassHealth ended GLP-1 coverage for weight loss for about 22,000 members on July 1, 2026, while continuing coverage for type 2 diabetes, sleep apnea with obesity, MASH and cardiovascular risk reduction ^[1]. Not every move has been a cut: North Carolina stopped covering Wegovy and Zepbound solely for obesity on October 1, 2025, but KFF reports obesity coverage was reinstated in December 2025 ^[1].

Why the diabetes side is untouched

Federal law is the reason the cuts stop where they do. Under 42 U.S.C. § 1396r-8(d)(2)(A), part of the 1990 Medicaid drug rebate statute, states may exclude "agents when used for anorexia, weight loss, or weight gain" from their formularies ^[1]. The law permits exclusion; it does not require it, and it does not extend to drugs used for diabetes ^[1]. That is why every state Medicaid program covers tirzepatide as Mounjaro for type 2 diabetes, usually with prior authorization, even as obesity coverage shrinks ^[1].

Some states cover a GLP-1 for a narrow non-obesity indication instead. West Virginia treats weight-loss agents as a benefit exclusion but covers Zepbound for obstructive sleep apnea in adults with obesity, effective July 1, 2025 ^[1]. Louisiana's criteria, dated June 5, 2025, cover adults 18 and older with moderate-to-severe sleep apnea and a BMI of 30 or more, without diabetes, with six-month approvals ^[1].

Why it matters for patients

"Covered" is not the same as approved. In states that still cover the obesity indication, the drug has to be on the preferred drug list and the prescriber has to meet prior authorization criteria, which commonly include documented diet and exercise efforts, a qualifying BMI, use alongside a reduced-calorie diet, and at least 5% weight loss to continue past the first six months ^[1]. Federal Medicaid managed care rules set outer limits of 72 hours for expedited prior authorization decisions and 14 calendar days for standard ones, and appeal windows run roughly 30 to 60 days depending on the state ^[1]. No state, CMS or MACPAC source publishes approval or appeal success rates specific to these drugs ^[1].

The counts themselves are slippery. KFF publishes its figure as a map rather than a list, and one aggregator counted 20 programs covering Wegovy or Zepbound for weight loss as of August 28, 2026, a number that conflicts with state bulletins for California, New Hampshire and Pennsylvania ^[1]. Any national tally is a starting point, not a substitute for a state's current preferred drug list ^[1].

Private coverage is not a reliable fallback. A 2024 KFF analysis found only 1% of Marketplace plans covered Saxenda or Wegovy for weight loss and none covered Zepbound; a review of 2026 plans found 26 carriers out of 300 nationwide covering GLP-1s for obesity, most limiting it to a BMI of at least 40 ^[2].

What happens next

October 1, 2026 is the next dated milestone, when Rhode Island's weight-management coverage is set to end. State formularies change quarterly, so further January 1, 2027 changes are possible but have not been announced in these sources.